相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci
Marianne Berg et al.
MOLECULAR CANCER (2010)
Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Martin Michaelis et al.
CANCER RESEARCH (2009)
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3a
Lioubov G. Korotchkina et al.
CELL CYCLE (2009)
Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells
Mitsuru Miyachi et al.
CLINICAL CANCER RESEARCH (2009)
MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Yoko Tabe et al.
CLINICAL CANCER RESEARCH (2009)
MDM2 regulates dihydrofolate reductase activity through monoubiquitination
Maria Maguire et al.
CANCER RESEARCH (2008)
E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines
M. Kitagawa et al.
ONCOGENE (2008)
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
L. M. S. Lau et al.
ONCOGENE (2008)
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Christoph R. Muller et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma
Elias Drakos et al.
CLINICAL CANCER RESEARCH (2007)
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1
G. Ambrosini et al.
ONCOGENE (2007)
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Man Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Franck Toledo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin
Baoli Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Hdmx modulates the outcome of P53 activation in human tumor cells
Mark Wade et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Eveline Barbieri et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Paola Secchiero et al.
BLOOD (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
Llorenc Coll-Mulet et al.
BLOOD (2006)
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3
JT Patton et al.
CANCER RESEARCH (2006)
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo
S Francoz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
C Cao et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
T Stühmer et al.
BLOOD (2005)
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors
D Carvajal et al.
CANCER RESEARCH (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics
A Aslanian et al.
GENES & DEVELOPMENT (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation
J Henriksen et al.
ONCOGENE (2003)
Management of malignant gastrointestinal stromal tumours
H Joensuu et al.
LANCET ONCOLOGY (2002)
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase
D Banerjee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines
P Perego et al.
CURRENT MEDICINAL CHEMISTRY (2001)
分享论文
